Valuation: BriaCell Therapeutics Corp.

Market Cap 32.8M 28.77M 26.64M 24.52M 46.37M 3.14B 47.27M 318M 125M 1.54B 123M 120M 5.32B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 14.93M 13.1M 12.13M 11.16M 21.11M 1.43B 21.52M 145M 56.7M 702M 56.07M 54.85M 2.42B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-4.48%
1 week+6.60%
Current month+14.87%
1 month+40.26%
3 months-12.48%
6 months-64.98%
Current year-45.61%
1 week 4.84
Extreme 4.84
5.64
1 month 3.81
Extreme 3.81
5.64
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
27.2
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 56 2021-04-30
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap.
Feb. 18Option

Chief Technology Officer

30,000 0.4830%
Feb. 18Option

Chief Financial Officer

30,000 0.4830%
Feb. 18Option

Chief Technology Officer

30,000 0.4830%
Change 5-day change 1-year change 3-year change Capi.($)
-4.48%+6.60%-80.90%-99.58% 34.33M
-2.48%-2.22%+55.85%+79.12% 54.88B
-0.55%-6.57%+58.09%+128.31% 54.63B
-5.60%-2.15%+11.16%+420.46% 25.06B
-1.55%-4.11%-20.21%-17.75% 23.14B
-1.34%+0.38%+38.02%-9.73% 19.87B
+1.87%+4.16%+38.13%-26.42% 17.55B
-2.72%-4.04%+187.08%+362.09% 16.5B
-0.83%-2.04%+46.88%+662.88% 15.75B
-0.81%+0.92%+24.92%+189.61% 14.2B
Average -1.75%+1.29%+35.90%+168.90% 24.16B
Weighted average by Cap. -1.61%-1.63%+48.23%+165.24%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.2M -3.89M -3.58M -6.77M -459M -6.91M -46.39M -18.2M -225M -17.99M -17.6M -778M -26.31M -23.08M -21.37M -19.67M -37.2M -2.52B -37.92M -255M -99.92M -1.24B -98.8M -96.64M -4.27B
Net Debt -862K -756K -700K -644K -1.22M -82.51M -1.24M -8.35M -3.27M -40.52M -3.24M -3.17M -140M -17.87M -15.67M -14.51M -13.35M -25.26M -1.71B -25.75M -173M -67.85M -840M -67.09M -65.62M -2.9B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-07-13 CA$5.330 -4.48% 7,357
26-07-10 CA$5.580 +7.93% 14,492
26-07-09 CA$5.170 -1.90% 6,875
26-07-08 CA$5.270 +7.11% 22,074
26-07-07 CA$4.920 -1.60% 6,434

Quarterly revenue - Rate of surprise